Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

• Main Authors: Dipak R. Patel (Author), Shweta Urva (Author), Stephen Ho (Author), Cody J. Buckman (Author), Yanfei Ma (Author), Jean Lim (Author), Sean E. Sissons (Author), Mary S. Zuniga (Author), Diane Philips (Author), Karen Cox (Author), Daniel J. Dairaghi (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with L...